Alnylam Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Alnylam Pharmaceuticals, Inc. – Product Pipeline Review, 2016’, provides an overview of the Alnylam Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.

The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Alnylam Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Alnylam Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Alnylam Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Alnylam Pharmaceuticals, Inc. Snapshot 6

Alnylam Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Alnylam Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Alnylam Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance 14

Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Alnylam Pharmaceuticals, Inc. - Drug Profiles 19

patisiran 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

revusiran 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ALN-PCSsc 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

fitusiran 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ALN-AAT 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ALN-CC5 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ALN-GO1 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ALN-HBV 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ALN-AS1 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ALN-TTRsc02 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ALN-VSP 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ALN-AC3 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ALN-AGT 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ALN-ANG 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ALN-PDL 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ALN-TMP 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Cellular Immunotherapy for Oncology and Viral Infections 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ALN-HDV 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

RNAi Oligonucleotide for Undisclosed Indication 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

RNAi Oligonucleotides for Genetic Diseases 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

RNAi Oligonucleotides for Hepatic Infections 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Alnylam Pharmaceuticals, Inc. - Pipeline Analysis 49

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target 49

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 51

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 52

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 53

Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates 55

Alnylam Pharmaceuticals, Inc. - Dormant Projects 83

Alnylam Pharmaceuticals, Inc. - Company Statement 84

Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries 86

Head Office 86

Other Locations & Subsidiaries 86

Appendix 87

Methodology 87

Coverage 87

Secondary Research 87

Primary Research 87

Expert Panel Validation 87

Contact Us 87

Disclaimer 88

List of Tables

List of Tables

Alnylam Pharmaceuticals, Inc., Key Information 6

Alnylam Pharmaceuticals, Inc., Key Facts 6

Alnylam Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Alnylam Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Alnylam Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Alnylam Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Alnylam Pharmaceuticals, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

Alnylam Pharmaceuticals, Inc. – Phase III, 2016 14

Alnylam Pharmaceuticals, Inc. – Phase II, 2016 15

Alnylam Pharmaceuticals, Inc. – Phase I, 2016 16

Alnylam Pharmaceuticals, Inc. – Preclinical, 2016 17

Alnylam Pharmaceuticals, Inc. – Discovery, 2016 18

Alnylam Pharmaceuticals, Inc. – Pipeline by Target, 2016 49

Alnylam Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 51

Alnylam Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 52

Alnylam Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 53

Alnylam Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 55

Alnylam Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 83

Alnylam Pharmaceuticals, Inc., Subsidiaries 86

List of Figures

List of Figures

Alnylam Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

Alnylam Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Alnylam Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Alnylam Pharmaceuticals, Inc. – Pipeline by Top 10 Target, 2016 49

Alnylam Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 51

Alnylam Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 52

Alnylam Pharmaceuticals, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 53

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports